For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Disability is the central theme of a new exhibition of paintings by the artist Lucy Jones, who creates brash, brightly ...

The results showed that psoriasis, wounds, dermatitis, and melanoma, topical ω-3 PUFAs provided overall beneficial effects linked to their anti-inflammatory action. No study reported skin irritation, ...